ROBERTI GLOBAL (F/K/A ROBERTI WHITE, LLC) for AMERISOURCEBERGEN CORPORATION
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Medicare/Medicaid MMM
Medicare prompt pay discount exclusion, including legislation to ensure appropriate reimbursement for drugs and biologics under Medicare Part B by excluding customary prompt-pay discounts extended to wholesalers from the manufacturer's Average Sales Price (ASP). ASP, generally Issues related to the HHS Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs Medicare Part D, including removal of safe harbor protection for drug rebates Medicare Part B, including proposals to create an international pricing index and establish a competitive acquisition program Prescription Drug Pricing Reduction Act (S. 2543); inclusion of bona fide service fees in ASP calculation under Medicare Part B.
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Pharmacy PHA
S. 988 and H.R. 803; legislation to prohibit prescription drug plan sponsors and MAPD organizations under Medicare program from retroactively reducing payment on clean claims submitted by pharmacies. Issues related to pharmaceutical compounding and implementation of the Drug Quality Security Act (Pub.L. 113-54). FDA implementation of Section 503B of the FFDCA. Issues related to drug pricing and transparency, generally. Issues related to the importation of prescription medicines
| Lobbyist | Covered position, as disclosed |
|---|---|
| STEVEN E IRIZARRY | — |
| VINCENT A. ROBERTI, SR. | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.